G01N 2333/94
Acting on alpha-galactose-glycoside bonds
Official title: acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
G01N2333/94 (Acting on alpha-galactose-glycoside bonds) appears on 15 US grants and 26 published applications in this corpus.
Search patents in G01N- Granted patents
- 15
- Published applications
- 26
- Assignees
- 14
- Inventors
- 30
- Latest grant
- 8 Feb 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 3 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 2 | 2 |
| 2016 | 1 | 3 |
| 2017 | 2 | 3 |
| 2018 | 1 | 3 |
| 2019 | 3 | 2 |
| 2020 | 2 | 0 |
| 2021 | 1 | 1 |
| 2022 | 1 | 2 |
| 2023 | 0 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Methods for treatment of Fabry disease8 Feb 2022US 11,241,422 B2Amicus Therapeutics, Inc.
- Method to predict response to pharmacological chaperone treatment of diseases29 Jun 2021US RE48,608 E1Amicus Therapeutics, Inc.
- Method to predict response to pharmacological chaperone treatment of diseases27 Oct 2020US 10,813,921 B2Amicus Therapeutics, Inc.
- Method for analyzing blood specimen, and analyzer11 Aug 2020US 10,739,360 B2National University Corporation Nagoya University
- Analytical method for determining the concentration of oxidized nanofibrillar cellulose in a sample31 Dec 2019US 10,520,485 B2Upm-Kymmene Corporation
- Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases13 Mar 2025US 2025/0082621 A9Amicus Therapeutics, Inc.
- Probes based on volatile organic compounds and uses thereof for the diagnosis and prognosis of pathological conditions31 Oct 2024US 2024/0361317 A1Centre Hospitalier Universitaire De Poitiers
- Assays for fabry disease treatment4 Jan 2024US 2024/0003901 A1Sangamo Therapeutics, Inc.
- Compounds and methods for the detection of fabry disease9 Feb 2023US 2023/0041689 A1Julius-Maximilians-UniversitäT WüRzburg
- Analysis method and analysis device15 Sep 2022US 2022/0291210 A1Hitachi High-Tech Corporation
Most cited
By later US patents
- Assays for diagnosing and evaluating treatment options for Fabry disease55US 7,851,143 B2Amicus Therapeutics, Inc. · 2010
- Method to predict response to pharmacological chaperone treatment of diseases54US 8,592,362 B2Amicus Therapeutics, Inc. · 2013
- Methods for treatment of Fabry disease51US 9,000,011 B2Amicus Therapeutics, Inc. · 2015
- Method to predict response to pharmacological chaperone treatment of diseases51US 9,095,584 B2Amicus Therapeutics, Inc. · 2015
- Methods for treatment of Fabry disease49US 10,383,864 B2Amicus Therapeutics, Inc. · 2019